<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B86BCE1F-CD9C-4BBE-890B-B544DD26890D"><gtr:id>B86BCE1F-CD9C-4BBE-890B-B544DD26890D</gtr:id><gtr:firstName>Anant</gtr:firstName><gtr:surname>Patel</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902006"><gtr:id>F5B3C53C-2E39-45FB-BE8D-2B19B3E03D2A</gtr:id><gtr:title>Relationships between Airway Infection, Exacerbations and Severity of Cardiovascular Risk in COPD</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902006</gtr:grantReference><gtr:abstractText>Chronic obstructive pulmonary disease (COPD) is a common lung condition and the modern term for emphysema and/or chronic bronchitis. It is most often caused by smoking. Many patients suffer from repeated flare-ups of COPD caused by chest infections.
People with COPD also have an increased risk of heart attack and stroke. This seems to be more than just due to smoking, and something to do with COPD itself. We would like to establish whether those patients with the most frequent flare-ups of COPD are at the most risk of heart attack and stroke.
Some patients with COPD have bacteria and/or viruses living in their airways even when they are well. We are also planning to investigate whether this group are at greater risk of heart attack and stroke.
One virus in particular called ?RSV? appears to be present in the lungs of around a quarter of COPD patients. Using laboratory experiments, we will investigate a possible link between the way the body reacts to this virus and a higher risk of heart attack and stroke</gtr:abstractText><gtr:technicalSummary>Chronic obstructive pulmonary disease (COPD) is characterised by recurrent acute exacerbations usually caused by airway infection. It has been shown that bacteria and to a lesser extent respiratory syncytial virus (RSV) colonise the lower respiratory tract of COPD patients.
There is excessive cardiovascular risk in COPD patients beyond smoking, however, the mechanism remains unclear.
We hypothesise that the severity of cardiovascular co-morbidity in COPD relates to the frequency of COPD exacerbations, and that cardiovascular risk may be modulated by the presence of airway infection both in the stable state and at exacerbation.
Key questions:
? Are those COPD patients suffering frequent exacerbations more at risk of cardiovascular disease?
? Is the magnitude of cardiovascular risk in stable COPD related to the presence of airway bacteria and/or viruses?
? Are there further changes in cardiovascular risk during exacerbations, and does the magnitude of this change relate to exacerbation aetiology?
? Do patients with airway RSV in the stable state have altered systemic inflammatory responses to exacerbation stimuli? Is there a link between airway colonisation, exacerbations, systemic inflammation and cardiovascular risk?
Using the MRC-funded London COPD Cohort, we can access patients for cardiovascular risk and airway infection assessment in the stable state, at exacerbation and at two weeks post-exacerbation.
Cardiovascular risk will be assessed by measuring carotid-femoral aortic pulse wave velocity, gold-standard non-invasive test. 12-lead ECGs will be scored using the Cardiac Infarction and Injury Scale. Blood markers sampled will include NT-proBNP, troponin, HbA1c, fasting glucose and lipids, fibrinogen and urine microalbuminuria.
Spontaneous or induced sputum will be collected in order to identify airway bacteria and viruses. Bacterial work, already funded by the MRC will be undertaken at UCL, using quantitative PCR, 16S rDNA amplification and sequencing, and genotyping of dominant species.
Quantitative RT-PCR for rhinovirus and qualitative RT-PCR multiplex for other viruses will be performed at UCL. Respiratory syncytial virus (RSV) RT-PCR and genotyping will be performed at Imperial College. 15 patients identified as RSV-colonised, and 15 non-colonised subjects will be studied further. We will investigate the inflammatory responses of peripheral blood leukocytes to exacerbation stimuli (rhinovirus, RSV, LPS and controls) employing colour flow cytometry (FACS).
This study will enable us to elucidate the role of airway infection and inflammation in the increased cardiovascular risk among COPD patients. If an aetiological link is shown, further studies ought to be undertaken to eradicate airway infection aimed at decreasing cardiovascular morbidity and mortality</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>223517</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Regional SpR Training</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2ADF9FB0-C8A9-4C4F-B11F-6D77F430F61E</gtr:id><gtr:impact>Multi-system involvement in COPD</gtr:impact><gtr:outcomeId>58b566537a5400.88598468</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to London-wide GPs and practice nurses</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C6397B4F-F6B5-4556-A3F9-38147F16C332</gtr:id><gtr:impact>Extensive discussions re metrics to record and act on in COPD,

Database linkage of comorbid conditions in some practices</gtr:impact><gtr:outcomeId>N8tBMhN6cdM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to local COPD patients in Camden</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>5302639D-BB75-4A87-8B55-CF35FB31308A</gtr:id><gtr:impact>100 COPD patients, and a few GP practice nurses listened to and discussed comorbidities in COPD and how they tend to affect people.

Patients volunteered for recruitment to the research study</gtr:impact><gtr:outcomeId>LrrUMK8BzzE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COPD Lecture to GPs (Teva)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F4E3E7D6-57D1-4106-9DD5-2904C00DA1F4</gtr:id><gtr:impact>Lecture and discussion with regional GPs</gtr:impact><gtr:outcomeId>58b5636d7682c4.82608075</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Lung Foundation Annual Report Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>81053D55-8588-4F32-A4D9-F0B5784839C4</gtr:id><gtr:impact>Interview for British Lung Foundation Annual Report</gtr:impact><gtr:outcomeId>58b567fedf8773.71818080</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to GPs from across the UK at an update course - St Thomas' Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>184A2B66-EE41-4D60-AFD1-8D9D43702FF1</gtr:id><gtr:impact>Presentation on recent NICE guidance, advances and theories in COPD and its comorbidities to 40 GPs - some members of PCRS

Increased awareness of optimal pharmacological and non-pharmacological therapies as well as the crucial impact of comorbidities.</gtr:impact><gtr:outcomeId>XLX5h4J68ZH</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to GPs</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>0A1F42BB-A2ED-4E50-A564-D587614C1B1E</gtr:id><gtr:impact>Presentation of preliminary data to several local GP groups emphasising the importance of comorbidities in COPD and leading to further recruitment of patients into the study.

Many more patients were recruited into the study as a result of these presentations and discussions.</gtr:impact><gtr:outcomeId>W4Mek3UpRj2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>APWV is a well-recognised non-invasive marker of cardiovascular risk. This measurement is performed in the stable state of the disease as well as at exacerbations and during recovery.</gtr:description><gtr:id>57771AE2-B183-4F30-BCBA-19E6F3318AE0</gtr:id><gtr:impact>Analysis in progress</gtr:impact><gtr:outcomeId>oRBYQsecpU8</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Aortic pulse wave velocity</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Database of lung function tests, health status measures, inflammatory markers, pusle wave velocity, ECG, cardiac biomarkers, urine microalbuminuria, sputum microbiology and virology.</gtr:description><gtr:id>CD3FD351-4B2E-40C9-86FA-62B4B6C8EF4A</gtr:id><gtr:impact>Analysis in progress</gtr:impact><gtr:outcomeId>LGeBQunvqRh</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database of health status measures, physiological tests and biological samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Sputum microbiology and virology is allied to symptom diary data to characterise exacerbations</gtr:description><gtr:id>15521A27-FDA3-4790-9EBD-120515FED34A</gtr:id><gtr:impact>Analysis in progress</gtr:impact><gtr:outcomeId>T4ZfE5Z539X</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mechanism of COPD Exacerbations</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7F84700D-B14E-4477-AF3A-420F4F0BCF0F</gtr:id><gtr:title>Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT).</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_12531_21_23988767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02C5CCD0-647E-4ED9-B97A-D7442941AA07</gtr:id><gtr:title>Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58b5616a8bdae2.82818096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F924EDDB-AA94-4C1F-9EA4-8436822CB627</gtr:id><gtr:title>Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art.</gtr:title><gtr:parentPublicationTitle>Expert review of respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee254fd9228e84336f32ea52d5b8010"><gtr:id>bee254fd9228e84336f32ea52d5b8010</gtr:id><gtr:otherNames>Patel AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1747-6348</gtr:issn><gtr:outcomeId>imnzPy4bxsG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC336C73-0ED1-4987-82C3-C37446C85D0B</gtr:id><gtr:title>Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_12531_21_22281834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A2E81E3-9B79-423E-A539-A873820365E4</gtr:id><gtr:title>The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a4d866cc668c8c82c4062d2e2b6add7"><gtr:id>7a4d866cc668c8c82c4062d2e2b6add7</gtr:id><gtr:otherNames>Patel ARC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>orz4ZwKVTr4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57946EB4-60A3-4AC0-98F1-B729CCCB6835</gtr:id><gtr:title>Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee254fd9228e84336f32ea52d5b8010"><gtr:id>bee254fd9228e84336f32ea52d5b8010</gtr:id><gtr:otherNames>Patel AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_12531_21_24033321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3AAE909-1927-45C9-97B8-BB2E740E51E9</gtr:id><gtr:title>Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68361379cb4d5e44a6e7514c816ffa78"><gtr:id>68361379cb4d5e44a6e7514c816ffa78</gtr:id><gtr:otherNames>Garcha DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_12531_21_22863758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>582C0CBD-D976-43E7-B0D3-25C4C7458C8C</gtr:id><gtr:title>Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db543f92bcffc0b658fc5987b469f7"><gtr:id>30db543f92bcffc0b658fc5987b469f7</gtr:id><gtr:otherNames>Hurst JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>aubinM9Z5AQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3507851-8634-45BB-93F4-6788CF60439A</gtr:id><gtr:title>Daily activity during stability and exacerbation of chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>58b56241317120.34787016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59A7DFA3-D712-4834-8D6D-0EACB875C0EF</gtr:id><gtr:title>Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddd38ca11db008642251078e0d028a02"><gtr:id>ddd38ca11db008642251078e0d028a02</gtr:id><gtr:otherNames>Singh R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>58b5626cd74686.71150775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CED013B-DF25-459A-A1EC-585495F11E0F</gtr:id><gtr:title>Human rhinovirus infection during naturally occurring COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97199d1962a5578ab0e7f99245ae7020"><gtr:id>97199d1962a5578ab0e7f99245ae7020</gtr:id><gtr:otherNames>George SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58b56299091e08.94464062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7571BE25-32CF-43B3-90A1-B9DA28737FB7</gtr:id><gtr:title>Influence of weather and atmospheric pollution on physical activity in patients with COPD.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>58b561f398edf1.03930005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>766CAF16-249D-4779-83EE-7BF7BDEA7741</gtr:id><gtr:title>Physical activity and exercise capacity in patients with moderate COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58b561852e79a8.24222720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF673414-BAC5-4E38-BC3D-3F18D41E904D</gtr:id><gtr:title>Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e951b4bd88680d58a75098fd5448ee8a"><gtr:id>e951b4bd88680d58a75098fd5448ee8a</gtr:id><gtr:otherNames>Brill SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>58b56218e1f4a7.95315297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA726FAA-7F88-4F9F-AEEA-34673ADA458A</gtr:id><gtr:title>Reduced lung-cancer mortality with CT screening.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee254fd9228e84336f32ea52d5b8010"><gtr:id>bee254fd9228e84336f32ea52d5b8010</gtr:id><gtr:otherNames>Patel AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12531_21_22111728</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902006</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>